 |
BioWorld-International-2007-12-12
Proximagen Deal With B-I Removes The 'For Sale' Sign
Proximagen Deal With B-I Removes The 'For Sale' Sign
LONDON - Investors in Proximagen Neurosciences plc resisted the lure of offers to buy the company and settled, for now, on a licensing agreement with Boehringer Ingelheim. (BioWorld International)
Start-Up Pharnext Raises €2.5M For Drug Repositioning Effort
No Abstract
BioWorld International Correspondent
PARIS - Pharnext, a start-up that is developing new treatments for severe neurological diseases, raised €2.5 million (US$3.68 million) in seed funding from the French venture capital firm Truffle Capital.